Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FiberChoice “badvertisement”

This article was originally published in The Tan Sheet

Executive Summary

Commercials for the dietary supplement FiberChoice (GlaxoSmithKline) and Rx cholesterol-lowering drugs Lipitor and Zetia are deemed the worst "badvertisements" by the Physicians Committee for Responsible Medicine in a recent release. "A recent crop of television commercials for supplements and drugs spin their quick-fix products as healthful alternatives to proper nutrition," PCRM says. The group claims, for example, that the FiberChoice ad "suggests that, unless you're eating broccoli, apples, and bran muffins all day, it is nearly impossible to get enough fiber." According to PCRM, firms should "only be permitted to give nutrition advice based on sound science"...

Commercials for the dietary supplement FiberChoice (GlaxoSmithKline) and Rx cholesterol-lowering drugs Lipitor and Zetia are deemed the worst "badvertisements" by the Physicians Committee for Responsible Medicine in a recent release. "A recent crop of television commercials for supplements and drugs spin their quick-fix products as healthful alternatives to proper nutrition," PCRM says. The group claims, for example, that the FiberChoice ad "suggests that, unless you're eating broccoli, apples, and bran muffins all day, it is nearly impossible to get enough fiber." According to PCRM, firms should "only be permitted to give nutrition advice based on sound science"....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel